The Beachbody Company Inc Stock Price, News & Analysis

Tiger Finance, in partnership with SG Credit Partners, has provided The Beachbody Company (NYSE:BODI) with a $35 million financing package. The three-year loan facility includes a $25 million immediate term loan and a $10 million uncommitted accordion. The funding allowed Beachbody to retire $17.3 million in outstanding debt and add $5 million to its balance sheet. The financing is designed to support the fitness and nutrition company's transition to a new business model and expansion in the digital fitness space. Beachbody's CEO Carl Daikeler emphasized that the funding provides liquidity to execute their strategy of opening new and more profitable distribution channels.

BODi (NYSE: BODI) reported its Q1 2025 financial results and secured a new $25 million three-year lending agreement with Tiger Finance. The company's Q1 revenue was $72.4 million, down from $120.0 million YoY, with a net loss of $5.7 million, improved from $14.2 million loss YoY. Gross margin improved to 71%, up 350bps from prior year. Digital subscriptions reached 1.02 million, while nutritional subscriptions were 0.08 million. The new lending agreement, executed on May 13, 2025, includes a $10 million uncommitted accordion and allowed BODi to retire $17.3 million of outstanding debt while adding $5 million to its balance sheet. The company achieved its sixth consecutive quarter of positive Adjusted EBITDA at $3.7 million. Management notes 2025 will be a transition year as they implement their new business model and strategic initiatives.

The Beachbody Company (NYSE: BODI), a leading fitness and nutrition company, has scheduled its first quarter 2025 earnings release for Wednesday, May 14, 2025, after market close. The company will host a conference call at 5:00 p.m. Eastern Time to discuss the results.

Investors can join via toll-free dial-in at (833) 470-1428 for U.S. & Canada, or through the company's investor relations website. A replay will be available from May 14 through May 21, 2025, accessible at (866) 813-9403.

Beachbody Company (NYSE: BODI) has received a notice of non-compliance from the New York Stock Exchange due to falling below required listing standards. The company failed to maintain both an average market capitalization of $50.0 million over a 30-day trading period and stockholders' equity of $50.0 million.

According to NYSE Manual Section 802.01B requirements, BODI must submit a business plan within 45 days demonstrating how it will regain compliance within 18 months. The company's securities remain listed on the NYSE during this period, subject to meeting other listing requirements. BODI has confirmed its intention to submit a compliance plan as required.

Beachbody (BODi) reported Q4 2024 financial results with total revenue of $86.4 million, reaching the high end of guidance despite declining from $119.0 million year-over-year. The company achieved a significant gross margin improvement of 830 basis points to 70.5%.

Q4 digital revenue was $50.4 million with 1.07 million subscriptions, while nutrition revenue reached $34.8 million with 90,000 subscriptions. The company reported a net loss of $34.6 million, including a $20.0 million goodwill impairment charge. Notably, BODi achieved its fifth consecutive quarter of positive Adjusted EBITDA at $8.7 million.

For full-year 2024, total revenue was $418.8 million with operating loss decreasing by $74.8 million to $66.2 million. The company successfully transitioned from a multi-level marketing network to a single-level affiliate model and generated positive operating cash flows of $2.6 million.

The Beachbody Company (NYSE: BODI), a leading fitness and nutrition company, has scheduled its fourth quarter 2024 earnings release for Thursday, March 27, 2025, after market close. The company will host a conference call at 5:00 p.m. Eastern Time to discuss the results.

Investors can join via toll-free dial-in at (833) 470-1428 (U.S. & Canada) with conference ID 112560, or through the live webcast on the company's investor relations website. A replay will be available from March 27 through April 3, 2025, accessible at (866) 813-9403 with passcode 284281.

The Beachbody Company (NYSE: BODI) and Hello Alpha have announced a strategic partnership combining BODi's lifestyle programs with Hello Alpha's virtual healthcare services. The collaboration focuses on integrating BODi's 140+ fitness programs and nutrition solutions with Hello Alpha's virtual medical care for 100+ conditions.

The partnership initially targets two key health areas:

• Hormone Health: Combining BODi's Belle Vitale program for hormone balance with Hello Alpha's hormone testing and medical guidance
• Weight Management: Integrating Hello Alpha's prescription medication services with BODi's exercise programs to maintain muscle mass during weight loss

Hello Alpha's patients will gain access to BODi's fitness and nutrition programs, while BODi members can receive medical support and personalized insights from licensed providers. The companies plan to expand their collaboration to additional health areas in the future.

The Beachbody Company (NYSE: BODI) has announced its participation in the upcoming 2025 ICR Conference. The company's leadership team, including Executive Chairman Mark Goldston, Co-Founder and CEO Carl Daikeler, and Interim CFO Brad Ramberg, will engage in a Fireside Chat on Tuesday, January 14, 2025, at 1:30pm EST.

Interested parties can access a live webcast of the presentation through the Investors section of the company's website. Investors seeking to schedule meetings with management are advised to contact their ICR representatives.

BODi (NYSE: BODI) has launched 'Belle Vitale,' a comprehensive 12-week lifestyle program designed by fitness expert Autumn Calabrese to address women's hormone health issues. The program combines fitness, nutrition, and stress reduction with proprietary supplements.

The program includes a 3-phase nutrition plan, 20 digital workouts combining Track Pilates and strength training, two proprietary supplement blends, and stress management tools through the Breathwrk app. Clinical testing showed participants experienced improvements in cortisol levels, metabolic markers, and weight loss.

The program targets common hormone imbalance symptoms affecting approximately 80% of women, including weight gain, hot flashes, irregular cycles, sleep disturbances, and mood swings.